Ferghana Partners
Ferghana Partners describes itself as an international investment banking and financial advisory group focused on the global life sciences sector. Its stated services include acquisitions, divestitures, corporate partnering, joint ventures and equity or other financings.
What stands out about Ferghana Partners
Ferghana Partners provides life sciences-focused advisory services across acquisitions, divestitures, corporate partnering, joint ventures, private placements, PIPEs and occasional debt or royalty-based financings. Publicly described capabilities include target and partner identification, diligence assistance, transaction structuring, negotiation support and preparation of transaction materials.[1][2][3][4][6]
What does Ferghana Partners do?
Ferghana Partners Group describes itself as an international investment banking and financial advisory group focused on the global life sciences sector. It advises on corporate partnering and business-portfolio matters including mergers, acquisitions, joint ventures and divestitures, and creates and executes financial transactions.[1]
Publicly described services include acquisition target identification, market research, confidential information collection, analysis, introductions, due-diligence assistance, transaction tactics and structure, and negotiation assistance. Ferghana also describes corporate-partnering support covering partner prioritization, non-confidential and confidential materials, diligence, finalist selection, deal terms and documentation. Its financing practice includes equity financings, primarily private placements and PIPEs, as well as occasional debt or royalty-based financings.[2][3][4]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Ferghana Partners?
A life-sciences owner evaluating Ferghana should clarify which legal entity would sign the engagement and perform each service, particularly where the mandate includes securities activity or a placement. The owner should also request the proposed buyer or partner universe, conflict-management approach, comparable assignments, fee and expense provisions, termination and tail terms, and the expected process from preparation through diligence and negotiation. The sources cited for this profile establish the firm’s life-sciences focus and described transaction capabilities, but they do not establish the terms of a particular engagement.[2][3][4][8]
Which Ferghana legal entity would sign the engagement and perform each service
What retainer, success fee, expense, tail and termination provisions would apply
Which recent transactions are comparable by therapeutic area, stage, geography and size
What size transactions and clients does Ferghana Partners focus on?
Ferghana identifies pharmaceuticals, biotechnology, diagnostics, medical devices, OTC drugs and specialty chemicals as areas within its life-sciences sector expertise.[1]
The official Transactions page lists Ferghana as adviser to Signature Diagnostics on its February 2015 sale to Roche Diagnostics Deutschland and to Pulsion Medical Systems on its February 2014 sale to the Getinge Group. It also lists a May 2014 $42 million equity/debt financing for AFT Pharmaceuticals, for which Ferghana acted as sole financial adviser; a January 2013 $28 million Series D equity financing for Crescendo Bioscience, for which it acted as financial adviser and sole placement agent; and its August 2009 role as sole adviser to Cephalon on its acquisition of Arana Therapeutics.[6]
The firm’s stated transaction focus spans mergers and acquisitions, divestitures, joint ventures, corporate partnering and financings. Its acquisition practice may support either a predefined-target mandate or a search for qualified targets, while its partnering process addresses partner identification, diligence, finalist selection and negotiation.[1][2][3]
What does Ferghana Partners publicly disclose about fees, process and engagement terms?
The cited official Transactions page does not state transaction consideration for the Signature Diagnostics–Roche, Pulsion–Getinge or Cephalon–Arana examples. The cited official Acquisitions page does not publish a universal minimum revenue, enterprise-value or transaction-size threshold. The cited official Financing page does not publish a standard fee schedule, success-fee percentage, minimum fee, tail period or termination schedule.[2][4][6]
FINRA’s firm-level BrokerCheck report identifies Ferghana Securities, Inc. as a Delaware corporation formed on April 22, 1997, with CRD #43430 and SEC #8-50270. The report states that the firm is currently registered with the SEC, one SRO and five U.S. states and territories, with SEC and FINRA registration effective February 27, 1998. The official firm page identifies Ferghana Securities Inc. as the U.S. securities entity, Ferghana Partners Inc. as covering the U.S., Canada and Australia/New Zealand, and Ferghana Partners LLP as the London-based entity covering the UK, Europe and Japan.[7][8]
Ferghana states that it may originate transaction ideas by suggesting targets based on a client’s strategic objectives and the relevant therapeutic, technological or industry sector. Its acquisition practice describes both a straight acquisition mandate for a predefined target and a two-phase assignment involving the search for and selection of one or a small number of qualified targets. The partnering process includes identifying and prioritizing potential partners, preparing materials, supporting diligence and finalist selection, establishing deal terms and negotiating documentation.[2][3]
Questions to ask before hiring Ferghana Partners
Which Ferghana legal entity would sign the engagement and perform each service?
What retainer, success fee, expense, tail and termination provisions would apply?
Which recent transactions are comparable by therapeutic area, stage, geography and size?
How broad would the proposed buyer or partner universe be, and how would conflicts be handled?
Would Ferghana act as an M&A adviser, placement agent, broker-dealer or corporate-partnering adviser for the proposed mandate?
What transaction values, consideration structures and closing outcomes can be shared under confidentiality?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Services / capabilities
- Services / capabilities
- Geography / market coverage
- Transaction / portfolio evidence
- FINRA regulatory record
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.